Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APS NYSEARCA:PBS CVE:RVV CVE:SVS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.63+1.2%C$1.86C$1.02▼C$17.40C$4.16M-0.0509885,063 shs2,535 shsPBSInvesco Next Gen Media and Gaming ETF$63.89-0.1%$62.14$30.95▼$40.10$58.14M1.225,287 shs2,352 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shsSVSSolarvest BioEnergyC$0.03C$0.02C$0.01▼C$0.14C$1.52M1.577,594 shs3,159 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+1.24%-3.55%-5.23%-8.94%-89.13%PBSInvesco Next Gen Media and Gaming ETF0.00%+1.19%+0.57%+10.15%+35.89%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%SVSSolarvest BioEnergy0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.63+1.2%C$1.86C$1.02▼C$17.40C$4.16M-0.0509885,063 shs2,535 shsPBSInvesco Next Gen Media and Gaming ETF$63.89-0.1%$62.14$30.95▼$40.10$58.14M1.225,287 shs2,352 shsRVVRevive TherapeuticsC$0.08+14.3%C$0.08C$0.07▼C$0.25C$5.79MN/A93,085 shs212,852 shsSVSSolarvest BioEnergyC$0.03C$0.02C$0.01▼C$0.14C$1.52M1.577,594 shs3,159 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences+1.24%-3.55%-5.23%-8.94%-89.13%PBSInvesco Next Gen Media and Gaming ETF0.00%+1.19%+0.57%+10.15%+35.89%RVVRevive Therapeutics0.00%0.00%0.00%0.00%0.00%SVSSolarvest BioEnergy0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/APBSInvesco Next Gen Media and Gaming ETF 2.68Moderate Buy$63.89N/ARVVRevive Therapeutics 0.00N/AN/AN/ASVSSolarvest BioEnergy 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$1.02 per share1.60C($0.92) per shareN/APBSInvesco Next Gen Media and Gaming ETFN/AN/AN/AN/AN/AN/ARVVRevive TherapeuticsN/AN/AC$0.03 per share3.18C$0.02 per shareN/ASVSSolarvest BioEnergyC$740.002,052.70C$0.00 per share55.00C($0.10) per share-0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$7.85N/A∞N/AN/A1,017.48%-136.29%N/APBSInvesco Next Gen Media and Gaming ETFN/AN/A33.42∞N/AN/AN/AN/AN/ARVVRevive TherapeuticsN/A-C$0.02N/A∞N/AN/AN/AN/AN/ASVSSolarvest BioEnergy-C$2.26M-C$0.04N/A∞N/AN/AN/A-143.12%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/APBSInvesco Next Gen Media and Gaming ETF$1.011.58%N/AN/AN/ARVVRevive TherapeuticsN/AN/AN/AN/AN/ASVSSolarvest BioEnergyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41PBSInvesco Next Gen Media and Gaming ETFN/AN/AN/ARVVRevive TherapeuticsN/A6.146.03SVSSolarvest BioEnergyN/AN/A0.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences0.02%PBSInvesco Next Gen Media and Gaming ETFN/ARVVRevive TherapeuticsN/ASVSSolarvest BioEnergyN/AInsider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%PBSInvesco Next Gen Media and Gaming ETFN/ARVVRevive TherapeuticsN/ASVSSolarvest BioEnergy15.85%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences312.55 millionN/ANot OptionablePBSInvesco Next Gen Media and Gaming ETFN/A910,000N/ANot OptionableRVVRevive TherapeuticsN/A72.41 millionN/ANot OptionableSVSSolarvest BioEnergyN/A60.76 millionN/ANot OptionableSVS, RVV, APS, and PBS HeadlinesRecent News About These CompaniesDiversified earnings streams to bolster SolarvestSeptember 8, 2025 | thestar.com.myTSolarvest expected to gain from upcoming RM2.5bil project pipelineSeptember 4, 2025 | thestar.com.myTMalakoff, Solarvest consortium shortlisted for Perak LSSPV projectSeptember 3, 2025 | thestar.com.myTSolarvest appoints Daniel Ruppert as CIOJuly 16, 2025 | thestar.com.myTSolarvest on track for strong FY26July 15, 2025 | thestar.com.myTSolarvest expands Asean footprint with Brunei’s solar power dealJune 17, 2025 | thestar.com.myTSolarvest to build 30MW solar project, Brunei’s largest PV plant to dateJune 16, 2025 | pv-tech.orgPSolarvest continues to make hay as the sun shinesJune 10, 2025 | thestar.com.myTA Look At The Intrinsic Value Of Solarvest Holdings Berhad (KLSE:SLVEST)May 27, 2025 | finance.yahoo.comSolarvest order book to surpass RM2bil in FY26May 21, 2025 | thestar.com.myTSolarvest optimistic orderbook to surpass RM2bil in FY26May 21, 2025 | thestar.com.myTMIDA Facilitates RM142 Mln Energy Partnership Between Solarvest, HSS & Shizen At Osaka ExpoApril 17, 2025 | bernama.comBWhile private companies own 23% of Solarvest Holdings Berhad (KLSE:SLVEST), individual investors are its largest shareholders with 32% ownershipApril 16, 2025 | finance.yahoo.comSolarvest order book hits record RM1.4bilMarch 27, 2025 | thestar.com.myTSolarvest maintains sunny outlookMarch 27, 2025 | thestar.com.myTSolarvest To Be Prime Beneficiary Of Large-scale Solar Contracts - HLIBMarch 27, 2025 | bernama.comBSolarvest unit wins RM103mil EPCC contractMarch 27, 2025 | thestar.com.myTSolarvest unit secures RM103.08mil EPCC contract for solar PV facility in Pulau PinangMarch 26, 2025 | thestar.com.myTUpbeat outlook for Solarvest on LSS5 plan shortlistMarch 21, 2025 | thestar.com.myTSolarvest subsidiary signs PPA for 60MWac solar PV facilityMarch 19, 2025 | thestar.com.myTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025These 4 Mid-Caps Just Announced Big Buyback PlansBy Leo Miller | September 9, 2025SVS, RVV, APS, and PBS Company DescriptionsAptose Biosciences TSE:APSC$1.63 +0.02 (+1.24%) As of 09/15/2025 11:57 AM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Invesco Next Gen Media and Gaming ETF NYSEARCA:PBS$63.89 -0.05 (-0.09%) As of 09/12/2025PowerShares Dynamic Media Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Media Intellidex Index (the Index). The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States media companies. These are companies that are principally engaged in the development, production, sale and distribution of goods or services used in the media industry. The Fund normally invests at least 90% of its total assets in common stocks that consists of the Index. The Fund's investment advisor is Invesco PowerShares Capital Management LLC.Revive Therapeutics CVE:RVVC$0.08 +0.01 (+14.29%) As of 07/22/2019Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.Solarvest BioEnergy CVE:SVSC$0.02 0.00 (0.00%) As of 09/5/2023Solarvest BioEnergy Inc. engages in the development of algal-based production systems to produce natural based green commercial products. It provides human nutrition products, including omega-3; clean energy production system that enables for continuous hydrogen production; and active ingredients for human health comprising cannabinoids in algae and bone morphogenetic protein for the treatment of repairing bone fractures. Solarvest BioEnergy Inc. has a collaborative research and development agreement with FSD Pharma Inc. to produce cannabidiol (CBD), Cannabigerol (CBG), and tetrahydrocannabinol (THC) programs. The company was incorporated in 2005 and is based in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
